Embed Size (px)
Citation preview
Τι «Class» πρεπει να εχει η ενδειξη της Καταλυσης της ΚολπικηςΜαρμαρυγης μετα τα δεδομενα απο τις προσφατα
δημοσιευμενες πολυκεντρικες μελετες;
Γεώργιος Κ. Ανδρικόπoυλος, MD, PhD, FESCΕρρίκος Ντυνάν Hospital Center
Presenter Disclosure Information
The presenter has received honoraria for participation in lectures and advisoryboards from the following pharmaceutical and biotechnology companies:
o AstraZeneca,
o Bard,
o Bayer Healthcare,
o Boehringer Ingelheim,
o Boston Scientific,
o Bristol-Myers Squibb,
o ELPEN,
o Galenica,
o Lilly,
o Medtronic,
o Menarini,
o MSD,
o Pfizer,
o Sanofi,
o Servier,
o StJude,
o Unifarma,
o Vianex.
(JACC Electrophysiology in press 2018)
Saksena S., et al. JACC 2011
Potential benefit of rhythm control offset by antiarrhythmic drug
toxicity
CABANA study, NEJM 2019
Catheter ablation vs His ablation and CRT(PABA-CHF trial)
Khan et al. NEJM 2008;359:1778-1785
Marrouche H, et al. New Eng J Med 2018:378(5);417-427
«Άπιστος Θωμάς»Michelangelo Merisi da Caravaggio
(1571–1610)
Marrouche H, et al. New Eng J Med 2018:378(5);417-427
Marrouche H, et al. New Eng J Med 2018:378(5);417-427
European Heart Journal Advance Access published May 20, 2016, doi:10.1093/eurheartj/ehw128
ΟΛΑ ΕΙΝΑΙ IIb η ΙΙΙ !!!
Ο Janus bifrons, δηλαδη διπροσωπος Ιανος
Ο θεος ολων των εναρξεων και των μεταβασεων
Catheter Ablation in HF
Recommendation for Catheter Ablation in HFCOR LOE Recommendation
IIb B-R
AF catheter ablation may be reasonable in selected patients with symptomatic AF and HF with reduced left ventricular (LV) ejection fraction (HFrEF) to potentially lower mortality rate and reduce hospitalization for HF.NEW: New evidence, including data on improved mortality rate, has been published for AF catheter ablation compared with medical therapy in patients with HF.
Τι «Class» πρεπει να εχει η ενδειξη της
Καταλυσης της Κολπικης Μαρμαρυγης μετα
τα δεδομενα απο τις προσφατα
δημοσιευμενες πολυκεντρικες μελετες;
IIa A I B I B
